Get started

Ovid Therapeutics Inc

At close
No trades
See on super-charts
Overview
News Ideas Financials Technicals Forecast

OVID chart

Key stats

Market capitalization
170.589MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.77USD

About Ovid Therapeutics Inc

ISIN
US6904691010
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
ovidrx.com
CEO
Jeremy Max Levin
Headquarters
New York
Employees
44
Founded
2014

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Ideas

Takeda Secures Global Rights from Ovid TherapeuticsTakeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome. Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial mile
OVID Could Potentially Bounce Back After losing most of its value, OVID sort of did nothing for the past month. However, recently it showed strong upside which makes me think it could bounce back eventually. If you like this idea, take a look at my idea on APRE and also look at UBX and how they bounced back. Target the $6 zone.
Long
buy rating and FDA Rare Pediatric Disease DesignationShares of Ovid Therapeutics were up by 29.1%, despite the company not reporting any news. The market is probably reacting to Ovid getting a buy rating from an analyst. --------------------------------------------------------- Michael Higgins, an analyst with Ladenburg Thalmann, reiterated a buy rati
$OVID Ovid Therapeutics, Inc. Inverse Head & Shoulders Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Long
2
$OVID Holding The Gap But Can it Sustain?One thing to look at especially when it comes to penny stocks is volume. If you look at this chart, OVID stock is holding above the previous gap zone. However, volume has consistently deteriorated. My question is can this sustain levels above the gap zone or are we looking at a further pullback? "
OVID - Going For A Run - Did You Catch It?Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY. SHORT INTEREST 272.51K 08/30/19. P/E Current -1.17 P/E Ratio (with extraordinary
Long
OVID - Bullish Momentum. Pullback Possible FirstOvid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY. SHORT INTEREST 426.41K 08/15/19 P/E Current -1.03 P/E Ratio (with extraordinary

See all ideas 

News flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
‪0‬
Revenue
‪0‬

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more